
CERC
Healthcare · Biotechnology · $285.0M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2021
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 2, 2021 | After the close | -0.19 | -0.18 | +3.6% |
| May 13, 2021 | After the close | -0.19 | -0.32 | -65.5% |
| Mar 8, 2021 | After the close | -0.15 | -0.16 | -6.7% |
| Nov 9, 2020 | After the close | -0.10 | -0.17 | -78.9% |
| Aug 6, 2020 | After the close | -0.10 | -0.19 | -81.0% |
| May 7, 2020 | After the close | -0.10 | -0.34 | -233.3% |
| Mar 11, 2020 | Before the open | -0.13 | 0.03 | +123.1% |
| Nov 14, 2019 | After the close | -0.13 | -0.07 | +47.5% |
| Aug 8, 2019 | After the close | -0.15 | -0.11 | +27.9% |
| May 9, 2019 | After the close | -0.16 | -0.13 | +20.4% |
| Mar 18, 2019 | Time not confirmed | -0.07 | -0.15 | -100.0% |
| Nov 13, 2018 | After the close | -0.12 | -0.71 | -491.7% |
| Aug 9, 2018 | Before the open | -0.10 |
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and…
| -0.19 |
| -90.0% |
| May 11, 2018 | After the close | -0.13 | -0.12 | +7.7% |